RTW Biotech Opportunities Ltd (LSE: RTWG), a London-listed investment fund focused on biopharmaceutical and medical technology assets, announced on 6 November 2026 that it repurchased 50,000 Ordinary Shares on 5 November 2026 at a price of $2.42 per share. The buyback was conducted under authority granted by shareholders at the company's Annual General Meeting in June 2026. The transaction increases the total number of Ordinary Shares held in treasury to 26,812,093, reducing the company's total voting rights to 319,155,347 — a figure investors will need to reference for FCA disclosure threshold calculations.

Key Points

  • RTW Biotech Opportunities Ltd (LSE: RTWG) — a healthcare-focused closed-ended investment fund managed by RTW Investments, LP
  • The company repurchased 50,000 Ordinary Shares on 5 November 2026 at $2.42 per share, to be held in treasury
  • Total issued share capital stands at 345,967,440, with 26,812,093 shares now in treasury carrying no voting rights
  • Investors should monitor further buyback disclosures ahead of the next AGM, expected in 2027, when shareholder authority will be renewed

50,000 Ordinary Shares Repurchased at $2.42 and Transferred to Treasury

RTW Biotech Opportunities Ltd confirmed the repurchase of 50,000 Ordinary Shares at $2.42 per share, executed on 5 November 2026 through its appointed broker, Jefferies International Limited. The shares will be held in treasury rather than cancelled, in line with the company's stated current intention. Treasury shares attract no voting rights, meaning the total voting share count has fallen to 319,155,347 following settlement. The company noted that no maximum consideration for the overall buyback programme has been formally determined, and that it cannot pay a price equating to a premium over net asset value.

June 2026 AGM Authority Permits Repurchase of Up to 14.99% of Ordinary Shares

The buyback is being conducted under authority granted at the company's Annual General Meeting held in June 2026, which permits RTW Biotech Opportunities Ltd to repurchase up to a maximum of 14.99% of its Ordinary Shares. This authority remains valid until the next shareholder approval, expected at the 2027 Annual General Meeting, or until shareholders expressly revoke it. The actual volume of shares repurchased under the programme will depend on prevailing market conditions, the announcement states. Jefferies International Limited has been instructed as broker for all buyback transactions, in accordance with FCA Listing Rules.

319,155,347 Voting Rights Figure Set as FCA Disclosure Denominator

Following the transaction and settlement, the total voting rights figure of 319,155,347 has been confirmed as the denominator shareholders should use when calculating whether they are required to notify a change in their interest under the FCA's Disclosure and Transparency Rules. With 26,812,093 shares now held in treasury out of a total issued capital of 345,967,440, investors holding or approaching reportable threshold levels in RTW Biotech Opportunities Ltd will need to update their calculations accordingly. The company is managed by RTW Investments, LP, a healthcare-focused investment firm with scientific expertise across biopharmaceutical and medical technology sectors.